Get started
Author

Fenlai Tan

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
2013 · Yuankai Shi, Li Zhang, et al. · The Lancet Oncology · 422
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
2011 · Fenlai Tan, Xiaoyan Shen, et al. · Lung Cancer · 134
Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study
2016 · Jing Huang, Qingxia Fan, et al. · Journal of Thoracic Oncology · 77
PDF
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors
2012 · Shaojing Hu, Guojian Xie, et al. · Bioorganic & Medicinal Chemistry Letters · 60
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
2016 · Shun Lu, Ming Ye, et al. · Oncotarget · 51
PDF
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
2014 · Xingsheng Hu, Baohui Han, et al. · Lung Cancer · 51
Icotinib, a Selective EGF Receptor Tyrosine Kinase Inhibitor, for the Treatment of Non-Small-Cell Lung Cancer
2015 · Fenlai Tan, Yuankai Shi, et al. · Future Oncology · 41
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study
2016 · Lin Zhou, Jiazhuo He, et al. · Lung Cancer · 40
Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
2011 · Han-ping Wang, Li Zhang, et al. · PubMed · 38
Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry
2009 · Dongyang Liu, Ji Jiang, et al. · Journal of Chromatography B · 31
Metabolite characterization of a novel anti‐cancer agent, icotinib, in humans through liquid chromatography/quadrupole time‐of‐flight tandem mass spectrometry
2011 · Dongyang Liu, Ji Jiang, et al. · Rapid Communications in Mass Spectrometry · 26
A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
2015 · Chao Lv, Chao An, et al. · Clinical Lung Cancer · 24
PDF
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
2023 · Caner Saygin, Giorgia Giordano, et al. · Clinical Cancer Research · 22
PDF
Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects
2014 · Dongyang Liu, Ji Jiang, et al. · Cancer Chemotherapy and Pharmacology · 21
PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)
2017 · Yi Long Wu, Jin -Ji Yang, et al. · Journal of Thoracic Oncology · 19
PDF
Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer
2015 · Dongyang Liu, Li Zhang, et al. · Lung Cancer · 15
Therapeutic Effects and Adverse Drug Reactions are Affected by Icotinib Exposure and CYP2C19 and EGFR Genotypes in Chinese Non-Small Cell Lung Cancer Patients
2014 · Jia Chen, Xin Zheng, et al. · Asian Pacific Journal of Cancer Prevention · 15
PDF
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia
2024 · Janani Ravikrishnan, Daisy Y. Diaz-Rohena, et al. · Haematologica · 14
Efficacy of icotinib in advanced lung squamous cell carcinoma
2018 · Shuai Liang, Yan Xu, et al. · Cancer Medicine · 14
PDF
First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).
2016 · Yuankai Shi, Lin Wang, et al. · Journal of Clinical Oncology · 14
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study
2015 · Xingsheng Hu, Li Zhang, et al. · PLoS ONE · 13
Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models
2017 · Fenlai Tan, Guiqun Yang, et al. · Biomedicine & Pharmacotherapy · 12
Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase
2023 · Jennifer A. Woyach, Deborah M. Stephens, et al. · Blood · 11
A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect
2010 · Caina Li, Yi Huan, et al. · Biochemical and Biophysical Research Communications · 11
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
2024 · Jennifer A. Woyach, Danielle M. Brander, et al. · Blood · 9
Works count: 99
Citation count: 1,305
H-index: 15
I10-index: 24
Year
Topic
Type